58 results about "Streptococcus lactis" patented technology

The invention relates to the technical field of aquaculture, in particular to nile tilapia ferritin, a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia ferritin is as shown in SEQ ID No.1, and the nile tilapia ferritin inhibits streptococcus agalactiae and / or aeromonas hydrophila. The invention provides Nile tilapia ferritin, and in-vitro experiments prove that the recombinant protein can effectively inhibit proliferation of pathogenic bacteria. A further in-vivo experiment research result shows that the ferritin heavy chain (Nile tilapia ferritin) has important functions of inhibiting pathogenic bacterium proliferation and improving the survival rate of an organism, and plays an important role in immune protection of the organism.

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention relates to the technical field of biology, in particular to a detection method for tilapia streptococcus agalactiae resistance, a KASP primer group and application. According to the invention, the key SNP site of the ABCB4 gene, which is obviously associated with the streptococcus agalactiae disease resistance, of the tilapia is identified by a population genetics method, a typing method of the SNP site is developed by a KASP technology, efficient evaluation on disease resistance characters is realized, experimental data shows that the survival time of an AA genotype individual in a challenge test is prolonged compared with that of a GA / GG genotype individual, and the survival time of the AA genotype individual in the challenge test is obviously prolonged compared with that of a GA / GG genotype individual. The proportion of resistant fishes is remarkably increased, and genotype frequency distribution is strongly related to group disease resistance. According to the breeding strategy based on the SNP marker, the disease resistance of bred groups can be integrally improved, the morbidity and death rate are reduced, an efficient genetic improvement tool is provided for breeding of tilapia mossambica for resisting streptococcus agalactiae diseases, the loss of breeding diseases is reduced, and antibiotic dependence is reduced.

The invention relates to the technical field of biology, in particular to an SNP (Single Nucleotide Polymorphism) marker combination for identifying tilapia streptococcus agalactiae disease resistance and application thereof. The invention discloses 11 SNP loci significantly related to streptococcus agalactiae resistance in a tilapia UTRN gene, and constructs 18 SNP marker combinations for streptococcus agalactiae resistance phenotype identification, so that the resistance phenotype identification accuracy and hereditary stability can be effectively improved. Besides, according to the SNP typing primer and method based on the # imgabs0 # MALDI-TOF mass spectrum platform, high-throughput and high-precision genetic typing can be achieved, and the SNP typing primer and method have important application value in resistance phenotype identification and assistant selective breeding.

Compositions comprising 5. salivarius strain SALI-10 and / or salivarius 10 peptide are taught. Also taught are methods of treating bacterial infections comprising administering a pharmaceutically acceptable amount of the composition to the patient with a bacterial infection caused by a pathogen from, for example, multi-drug resistant (MDR) Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus dysagalactiae, vancomycin-resistant Enterococcus faecium, Porphyromonas gingivalis, Tannerella forsythia, and MDR Enterococcus faecalis.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The present application relates to the field of biotechnology, and particularly relates to a KASP molecular marker related to the resistance of tilapia to streptococcus agalactiae disease and an application thereof.Two SNP sites (SNP-1 and SNP-2) significantly associated with the resistance are screened from the intron region of EGFRX2 gene of tilapia, a typing method of the above sites is developed through KASP technology, and the correlation between the SNP-1 genotype and the resistance phenotype is verified.Further, an advantage haplotype individual with the resistance to streptococcus agalactiae disease is screened by combining the two SNP sites, and the survival rate of the individual in the challenge experiment is significantly improved.The detection kit provided by the present application can realize high-throughput and high-precision typing, is suitable for the identification of the resistance genotype of tilapia and the marker-assisted selection, provides an efficient genetic improvement tool for the disease-resistant breeding of tilapia, and is helpful to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The invention discloses application of a series of isosteviol derivatives in preventing and treating pathogenic bacteria of cow mastitis, and belongs to the field of medicinal chemistry. According to the present invention, with the application of the derivative of the present invention, the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957 can be provided, and the application of the derivative of the present invention provides the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957, the synthesis method of the compound is simple, the raw materials are cheap and easy to obtain, and the compound has great development value in the aspect of natural product source compounds for preventing and treating cow mastitis. The structural formula of the compound is shown in the specification.

The invention discloses a streptococcus agalactiae attenuated strain, a vaccine and application of the streptococcus agalactiae attenuated strain, and belongs to the technical field of veterinary biological products. The streptococcus agalactiae attenuated strain is obtained by knocking out a marR gene of a streptococcus agalactiae virulent strain HN016; wherein the nucleotide sequence of the marR gene is as shown in SEQ ID NO: 1. After the marR gene of the streptococcus agalactiae virulent strain HN016 is knocked out, the streptococcus agalactiae attenuated strain of which the virulence is remarkably reduced is obtained, and after the streptococcus agalactiae attenuated strain is prepared into the vaccine, the survival rate of aquatic animals infected with streptococcus agalactiae can be remarkably improved, so that the survival rate of the aquatic animals infected with streptococcus agalactiae is improved. The streptococcus agalactiae attenuated strain has a good application prospect in preparation of drugs for preventing and / or treating streptococcus agalactiae infection of aquatic animals.

The present application relates to a Pediococcus acidilactici capable of reducing the activation of hippocampal microglia cells and its application, belonging to the technical field of microorganisms. The Pediococcus acidilactici described in the present application is Pediococcus acidilactici CCFM1344, which was preserved in the Guangdong Microbial Culture Collection Center on September 12, 2023, with the preservation number GDMCC NO.63800. The preservation address is Building 59, 5th Floor, Guangdong Microbial Institute, 100 Middle Martyrs Road, Guangzhou. The Pediococcus acidilactici described in the present application can inhibit the over-activation of microglia cells caused by chronic stress, reduce the concentration of pro-inflammatory factors in the hippocampus of the brain, thereby relieving the activation of microglia cells in the hippocampus of the brain caused by chronic stress, and has excellent application prospects.

The invention relates to the field of microorganisms, in particular to a streptococcus lactis strain SKLAN202403XW for degrading solanine and application of the streptococcus lactis strain SKLAN202403XW. The preservation number of the strain is CGMCC No.30021. The strain and a preparation thereof can effectively reduce the content of solanine in potato stems and leaves, significantly reduce the toxicity of the potato stems and leaves, and provide a basis for subsequent development and utilization.

The application discloses a recombinant strain and a preparation method thereof and application of the recombinant strain in preparation of a vaccine for Streptococcus agalactiae of tilapia, and the recombinant strain is successfully constructed by the following steps: designing an ORF4 primer, amplifying an ORF4 gene fragment from a DNA template of Streptococcus agalactiae, editing the ORF4 gene fragment into Escherichia coli by means of a CRISPR / Cas9 gene editing technology, and connecting a green fluorescent protein (GFP). The recombinant strain is subjected to immunoprotection research on the Streptococcus agalactiae of tilapia, and it is shown that the recombinant strain has a good protection effect, and can provide a solid theoretical basis and technical support for application and development of the vaccine for Streptococcus agalactiae of tilapia in the field of aquaculture.

The present application relates to the field of biotechnology, and more particularly to a detection method for resistance of tilapia to streptococcosis, a KASP primer set and application. The present application identifies a key SNP site of the ABCB4 gene significantly associated with resistance of tilapia to streptococcosis by the method of population genetics, and develops a genotyping method for the SNP site by KASP technology, thereby realizing efficient evaluation of the disease-resistant trait. Experimental data show that the survival time of AA genotype individuals in the challenge test is longer than that of GA / GG genotype individuals, the proportion of resistant fish is significantly improved, and the genotype frequency distribution is strongly correlated with the disease resistance of the population. The breeding strategy based on the SNP marker can improve the overall disease resistance of the breeding population and reduce the mortality rate, thereby providing an efficient genetic improvement tool for breeding of tilapia resistant to streptococcosis, and helping to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The present application relates to the technical field of microorganism, and particularly relates to a streptococcus lactis with a cat dandruff treatment function and application thereof. Pediococcus acidilactici The streptococcus lactis is preserved in the Guangdong Provincial Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67035. The streptococcus lactis and the inactivated bacteria solution provided in the present application have good inhibitory effects on trichophyton mentagrophytes and mycosporum gypseum. The streptococcus lactis provided in the present application can also be used for treating cat dandruff, and compared with ketoconazole cream, the streptococcus lactis has faster effect and shorter treatment cycle.

The invention discloses a bifidobacterium animalis subsp. Lactis BT-G9 with a growth promoting function and application of the bifidobacterium animalis subsp. Lactis BT-G9, the bifidobacterium animalis subsp. Lactis BT-G9 is preserved in China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252626. The brand new bifidobacterium animalis subsp. Lactis BT-G9 provided by the invention has good tolerance to gastric juice and intestinal juice, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter kirscheri, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can promote animal growth and development and improve the autism, especially when the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 are combined for use, the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 have a synergistic effect, and the improvement effect on the autism can be remarkably improved. In addition, the extracellular vesicles prepared from the strain can effectively repair the skin barrier function.

The application belongs to the technical field of biological medicine, and particularly relates to application of pantothenic acid or a pharmaceutically acceptable salt thereof in preparation of a medicine for enhancing sensitivity of pathogenic bacteria to daptomycin. It is found for the first time that addition of pantothenic acid or a pharmaceutically acceptable salt thereof can improve the sensitivity of gram-positive bacteria including Staphylococcus aureus, Streptococcus agalactiae and Corynebacterium diphtheriae to daptomycin, significantly improve the bactericidal effect, and further research shows that pantothenic acid or a pharmaceutically acceptable salt thereof can promote the clearance, formation and reduction of pathogenic bacteria biofilm by daptomycin. The finding opens up a new way for overcoming antibiotic resistance and optimizing anti-infection treatment strategies.

The invention discloses a novel application of Xenocoumacin 1 in prevention and treatment of pathogenic bacteria of cow mastitis, and belongs to the field of natural pharmaceutical chemistry. According to the present invention, with the application of the Xenocoumacin 1, the broad-spectrum and efficient inhibition activity can be provided for the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC27956, Streptococcus dysgalactiae ATCC27957, Escherichia coli ATCC 25922, and Staphylococcus aureus (Staphylococcus aureus), and the broad-spectrum and efficient inhibition activity can be provided for the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC27956, Streptococcus dysgalactiae ATCC27957, Escherichia coli ATCC 25922, and Staphylococcus aureus (Staphylococcus aureus); therefore, the Xenocoumacin 1 has development potential in the aspect of being developed into the natural source medicine for preventing and treating the cow mastitis.

The invention provides a fermentation method for improving titer of nisin, which comprises the following steps of: performing seed culture on a nisin seed solution, transferring the nisin seed solution into a fermentation culture medium, performing fermentation culture, and achieving a manner of improving the titer through a fermentation method of feeding, supplementing materials and introducing air. In the fermentation process, a 5% (g / L) phytic acid solution is added in a fed-batch mode when the period is 10-16 h till fermentation is finished. Before the fermentation period is 14 hours, air is not introduced for culture, the tank pressure is 0 Mpa, 0.01-0.05 vvm of air is introduced from 14 hours, and the tank pressure is 0.03 Mpa until the fermentation is finished. The phytic acid solution is supplemented in the middle and later periods of fermentation, the metabolism speed can be controlled, thallus oxidation death and autolysis are prevented, and the biological value is indirectly improved. A trace amount of air is introduced, so that the generation of lactic acid can be inhibited, tricarboxylic acid circulation is properly enhanced, and the synthesis efficiency of precursor amino acid is improved. Under the combined action of the two, the effects of controlling and prolonging the primary metabolism time, reducing the yield of lactic acid and obviously improving the titer increase in the later period are achieved.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The invention discloses a lactobacillus plantarum bacteriostatic agent and application thereof, and relates to the technical field of microbial engineering. According to the lactobacillus plantarum LP2301 provided by the invention, fermentation liquor of the lactobacillus plantarum LP2301 can be used for effectively inhibiting aquatic pathogenic bacteria streptococcus agalactiae, limiting the growth of the streptococcus agalactiae, reducing the use of antibiotics, ensuring food safety and guaranteeing the health of animals and human beings by secreting metabolites such as bacteriostatic proteins and organic acids. Secondly, the invention provides an application of the lactobacillus plantarum bacteriostatic agent, and the lactobacillus plantarum LP2301 is compounded into the bacteriostatic agent; through multi-target cooperation of the cortex phellodendri extract and the rosmarinic acid, the antibacterial efficiency of single probiotics is remarkably optimized; active ingredients of cortex phellodendri directionally destroy a biological membrane barrier of streptococcus agalactiae and disintegrate an adhesion defense system of pathogenic bacteria; rosmarinic acid blocks a bacterial energy metabolism pathway synchronously, so that pathogens lose proliferative power; and exclusive bacteriocin secreted by the LP2301 accurately breaks down a cell membrane structure, so that fatal killing is realized.

The present application relates to the field of aquaculture technology, in particular to a tilapia nilotica ferritin, a preparation method and application thereof, and a bacteriostatic agent.The amino acid sequence of the tilapia nilotica ferritin is shown as SEQ ID No.1, and the tilapia nilotica ferritin can inhibit Streptococcus agalactiae and / or Aeromonas hydrophila.The present application provides the tilapia nilotica ferritin, and in-vitro experiments have proved that the recombinant protein can effectively inhibit the proliferation of pathogenic bacteria.Further in-vivo experimental results show that the ferritin heavy chain (tilapia nilotica ferritin) has the important functions of inhibiting the proliferation of pathogenic bacteria and improving the survival rate of the organism, and plays an important role in the immune protection of the organism.

The present invention discloses a method for preparing a eukaryotic expression vector of Nile tilapia CD36 protein and its application. The method comprises extracting RNA from Nile tilapia intestinal tissue and synthesizing cDNA; performing PCR amplification on the coding sequence fragment of the Nile tilapia CD36 gene to obtain the Nile tilapia CD36 protein gene; and then constructing a eukaryotic expression vector pEGFP-N1-CD36 of the Nile tilapia CD36 protein. The eukaryotic expression vector of the nucleotide sequence of the Nile tilapia CD36 protein prepared by the present invention can be used to prepare a product that improves the anti-streptococcal immunity of tilapia. The preparation of the product is simple, easy to operate, and low in cost. The present invention enhances the anti-streptococcal ability of tilapia by overexpressing the Nile tilapia CD36 protein in tilapia, thereby increasing the survival rate of tilapia infected with Streptococcus agalactiae by 60%. In addition, overexpressing the Nile tilapia CD36 protein in tilapia can also reduce the Streptococcus agalactiae load in tilapia. Therefore, it can be seen that the technical solution of the present invention can effectively induce cellular immunity in tilapia.

The invention discloses a compound cefquinome sulfate mammary gland perfusion agent and a preparation method thereof, and the compound cefquinome sulfate mammary gland perfusion agent comprises the following components in parts by mass: 60mg of cefquinome sulfate, 90mg of inositol, 80mg of a suspending aid, 120mg of a wetting agent, 4mg of an antioxidant, and the balance of a non-aqueous solvent, totaling 8g. The main drug in the preparation is a fourth-generation animal special cephalosporin antibiotic-cefquinome sulfate, has a broad-spectrum bactericidal effect and is effective to gram positive and gram negative strains including beta-lactamase-producing strains, and bacteriostasis experiments prove that the preparation has a strong antibacterial effect on various microorganisms causing cow mastitis, and can be used for preventing and treating cow mastitis. The composition especially has special effects on streptococcus uberis, streptococcus dysgalactiae, staphylococcus aureus and the like.

The invention provides a tilapia mossambica antibacterial peptide OnLEAP-2 and application thereof, an antibacterial peptide named OnLEAP-2 is cloned from tilapia mossambica, and a large number of antibacterial peptides are obtained through prokaryotic expression. The antibacterial peptide has a very good function of resisting streptococcus agalactiae, so that the survival rate of tilapia mossambica is remarkably increased, and pathogens are efficiently removed. The composition is suitable for bacterial disease control of economic fishes such as tilapia.

The present invention relates to compositions and methods for detecting group B streptococcus (GBS, Streptococcus agalactiae) and identifying the most common genes responsible for clindamycin resistant GBS, such as ermB, ermTR, ermT, lsaC and lsaE, by multiplex real-time PCR assays.

The invention relates to the technical field of biology, and particularly discloses streptococcus dysgalactiae and a preparation method and application of a streptococcus dysgalactiae egg yolk antibody, the streptococcus dysgalactiae is preserved in China General Microbiological Culture Collection Center on December 24, 2024, and the preservation number is CGMCC No.46272; the preparation method of the streptococcus dysgalactiae egg yolk antibody comprises the following steps: preparing a streptococcus dysgalactiae antigen, and carrying out vaccine distribution treatment on the antigen to obtain a streptococcus dysgalactiae vaccine; carrying out intramuscular injection on the chicken with a streptococcus dysgalactiae vaccine, and carrying out immune treatment; identifying the titer of the egg yolk, determining that the egg yolk accords with antibody preparation, then cleaning and disinfecting, and then air-drying; egg yolk and egg white are separated from the air-dried eggs, the egg yolk is pretreated with a disodium hydrogen phosphate solution, then acidification extraction, filtration sterilization and detection are conducted, and egg yolk antibodies are obtained; the compound is used for preventing and treating streptococcus dysgalactiae infection of pigs; the control effect is good.

The invention relates to the technical field of agricultural biology, in particular to application of protein 2370 in degradation of solanine. The amino acid sequence of the protein is shown as SEQ ID NO: 1. The streptococcus lactis strain SKLAN202403XW is obtained through identification and separation in potato planting soil, biological protein is obtained from the strain, solanine can be efficiently decomposed, the content of solanine can be remarkably reduced, the toxicity of potato stems and leaves is reduced, and a foundation is provided for subsequent development and utilization.

The invention discloses application of a series of steviol derivatives in preventing and treating pathogenic bacteria of cow mastitis, and belongs to the field of medicinal chemistry. According to the present invention, with the application of the derivative, the excellent inhibition activity on the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 12386 and Streptococcus dysgalactiae ATCC 27957 can be provided, and the derivative can be used for the preparation of the dairy cow mastitis pathogenic bacteria such as Streptococcus agalactiae ATCC 27957, the synthesis method of the compound is simple, the raw materials are cheap and easy to obtain, and the compound has great development value in the aspect of natural product source compounds for preventing and treating cow mastitis. The structural formula of the compound is shown in the specification.

The invention relates to the technical field of agricultural biology, in particular to application of a protein 0604 capable of efficiently degrading solanine to degradation of solanine. The amino acid sequence of the protein is shown as SEQ ID NO: 1. The streptococcus lactis strain SKLAN202403XW is obtained through identification and separation in potato planting soil, biological protein is obtained from the strain, solanine can be efficiently decomposed, the content of solanine can be remarkably reduced, the toxicity of potato stems and leaves is reduced, and a foundation is provided for subsequent development and utilization.